Skip to main content
  • Register
  • Help
  • Contact us

Oasmia Pharmaceutical AB (OASM) NPV

Sell:3.45 SEK Buy:3.45 SEK Change: 0.09 SEK (2.68%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Sell:3.45 SEK
Buy:3.45 SEK
Change: 0.09 SEK (2.68%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Sell:3.45 SEK
Buy:3.45 SEK
Change: 0.09 SEK (2.68%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Oasmia Pharmaceutical AB is a Sweden-based pharmaceutical company engaged in the field of human and veterinary oncology. The Company’s activities are divided into two segments: Human Health and Animal Health. The Human Health segment specializes in ovarian and breast cancer. The Animal Health area focuses on developing cancer treatments for dogs. Its drugs portfolio comprises six candidates: Paclical, Doxophos, Docecal and OAS-19, which are implemented in human treatment, as well as Paccal Vet-CA1 and Doxophos Vet, introduced in cancer in dogs. The Company’s medicines are based on the patented XR-17 excipient, which forms micelles with water-soluble substances. Furthermore, It cooperates with Abbott Laboratories, Pharmasyntez, Nippon Zenyaku Kogyo and Medison Pharma. The Company is a parent of Oasmia Global Supplies AB and Oasmia Animal Health AB.

Contact details

Vallongatan 1
752 28
+46 (18) 505440

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
1.50 billion SEK
Shares in issue:
448.37 million
Stockholm Stock Exchange
Swedish Krona

Key personnel

  • Jorgen Olsson
    Chairman of the Board
  • Francois Martelet
    Chief Executive Officer
  • Fredrik Jarrsten
    Chief Financial Officer
  • Anette Sjodin
    Executive Vice President
  • Mikael Asp
    Chief Technology Officer
  • Magdalena Berg
    Head of Accounting
  • Dzianis Babrou
    Head of Product Development
  • Nina Heldring
    Head of Clinical Development
  • Maria Nilsson Hagberg
    Head of Regulatory Affairs
  • Henrik Ronnberg
    Chief Medical Officer Animal Health

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.